Biopharmaceutical Manufacturing, Upstream, Downstream …
2024年12月19日 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
News - biopharma-reporter.com
2024年12月10日 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
How will the Biosecure Act impact the pharma industry?
2024年10月8日 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China.
All news articles for January 2024 - biopharma-reporter.com
2024年1月2日 · Carolina Gonzalez on pharma packaging and the lack of female leaders on her path. 31-Jan-2024 By Liza Laws . Carolina is responsible for the consulting department at Genesis Packaging Technologies where she designs package characterization studies.
Cell and gene therapy will be top industry trend for pharma in 2024
2024年1月8日 · Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.
BioPharmaReporter gets a new look
2024年11月26日 · We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t change, but we’ve tweaked the look and feel of the site to bring you improved navigation, more content-rich articles, enhanced search capabilities and a better browsing experience.
Trends in biosimilars: Regulatory approvals in 2024
2024年7月24日 · The biosimilars market is rapidly growing as global demand for biosimilars continues to grow. The global biosimilar market is estimated to reach a size of $43.8 billion by the end of 2024, and to grow over $100 billion in the next 10 years.. Biologics are expensive medications, which is driving up the popularity of biosimilars as a more cost-effective alternative.
About us - biopharma-reporter.com
About Biopharma Reporter. Biopharma Reporter is an essential resource for the biopharma industry, covering large molecules (biologics). We focus on the key trends shaping this dynamic sector, including contract research organizations, patient-centric innovations, AI-driven data management, and the rapidly evolving landscape of cell and gene therapies.
Biosimilar producer looking to get first to market advantage in …
2021年6月23日 · Bio-Thera Solutions recently initiated a Phase 3 trial of its proposed golimumab biosimilar BAT2506 in China and Eastern Europe, making it the first subcutaneous golimumab biosimilar to do so in multiple countries, according to a report from GlobalData.
EY: Signs biopharma industry ready to return to the big …
2023年1月12日 · EY research found that, for the first 11 months of 2022, biopharma M&A value dropped 42% compared with 2021. “Alliances remain a significant focus for biopharma and companies’ M&A strategies.However, Amgen’s mid-December announcement that it will pay more than US$28 billion for Horizon Therapeutics may be a signal that the industry is ready to return to the big dealmaking table in 2023.”